» Articles » PMID: 31698826

When Does Alzheimer's Disease Really Start? The Role of Biomarkers

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2019 Nov 9
PMID 31698826
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

While Alzheimer's disease (AD) classical diagnostic criteria rely on clinical data from a stablished symptomatic disease, newer criteria aim to identify the disease in its earlier stages. For that, they incorporated the use of AD's specific biomarkers to reach a diagnosis, including the identification of Aβ and tau depositions, glucose hypometabolism, and cerebral atrophy. These biomarkers created a new concept of the disease, in which AD's main pathological processes have already taken place decades before we can clinically diagnose the first symptoms. Therefore, AD is now considered a dynamic disease with a gradual progression, and dementia is its final stage. With that in mind, new models were proposed, considering the orderly increment of biomarkers and the disease as a continuum, or the variable time needed for the disease's progression. In 2011, the National Institute on Aging and the Alzheimer's Association (NIA-AA) created separate diagnostic recommendations for each stage of the disease continuum-preclinical, mild cognitive impairment, and dementia. However, new scientific advances have led them to create a unifying research framework in 2018 that, although not intended for clinical use as of yet, is a step toward shifting the focus from the clinical symptoms to the biological alterations and toward changing the future diagnostic and treatment possibilities. This review aims to discuss the role of biomarkers in the onset of AD.

Citing Articles

Association between BrainAGE and Alzheimer's disease biomarkers.

Abughofah Y, Deardorff R, Vosmeier A, Hottle S, Dage J, Dempsey D Alzheimers Dement (Amst). 2025; 17(1):e70094.

PMID: 40018325 PMC: 11865712. DOI: 10.1002/dad2.70094.


Glutamate: Molecular Mechanisms and Signaling Pathway in Alzheimer's Disease, a Potential Therapeutic Target.

Puranik N, Song M Molecules. 2024; 29(23).

PMID: 39683904 PMC: 11643865. DOI: 10.3390/molecules29235744.


Identifying Alzheimer's disease-associated genes using PhenoGeneRanker.

Rahman M, Saeed F, Bozdag S bioRxiv. 2024; .

PMID: 39605436 PMC: 11601490. DOI: 10.1101/2024.11.12.623269.


Mechanisms and Functions of the Cerebral-Cognitive Reserve in Patients with Alzheimer's Disease: A Narrative Review.

Sidenkova A, Litvinenko V, Bazarny V, Rezaikin A, Zakharov A, Baranskaya L Consort Psychiatr. 2024; 5(3):17-29.

PMID: 39526013 PMC: 11542915. DOI: 10.17816/CP15526.


Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease.

Safransky M, Groh J, Blennow K, Zetterberg H, Tripodis Y, Martin B Neurology. 2024; 103(11):e209866.

PMID: 39496102 PMC: 11540457. DOI: 10.1212/WNL.0000000000209866.


References
1.
Jack Jr C, Lowe V, Weigand S, Wiste H, Senjem M, Knopman D . Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009; 132(Pt 5):1355-65. PMC: 2677798. DOI: 10.1093/brain/awp062. View

2.
Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel S . CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006; 129(Pt 11):3035-41. DOI: 10.1093/brain/awl269. View

3.
Anastasio T . Exploring the contribution of estrogen to amyloid-Beta regulation: a novel multifactorial computational modeling approach. Front Pharmacol. 2013; 4:16. PMC: 3585711. DOI: 10.3389/fphar.2013.00016. View

4.
Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

5.
Johnson K, Gregas M, Becker J, Kinnecom C, Salat D, Moran E . Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007; 62(3):229-34. DOI: 10.1002/ana.21164. View